On August 4, 2025, the Issuer entered into a securities purchase agreement with certain institutional accredited investors ("PIPE Investors"), pursuant to which, the Issuer agreed to issue and sell to the PIPE Investors in a private placement an aggregate of 15,225,158 Shares and, to certain PIPE Investors, pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 37,410,188 Shares and, in each case, accompanying warrants (the "Common Warrants" and, together with the Pre-Funded Warrants, the "Warrants") to purchase up to an aggregate of 52,635,346 Shares, or in lieu thereof, Pre-Funded Warrants (the "PIPE"). The Warrants contain an exercise limitation that prohibits the holder from exercising the Warrants to the extent that after giving effect to such issuance after exercise the holder would beneficially own in excess of 9.99% of the number of Shares outstanding immediately after giving effect to the issuance of the Shares issuable upon exercise of the Warrants (the "Blocker"). The price per Share and accompanying Common Warrant is $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant is $0.8676. The PIPE closed on August 25, 2025. In connection with the PIPE, OrbiMed Private Investments IX, LP ("OPI IX"), a limited partnership organized under the laws of Delaware, purchased 5,255,106 Shares and 10,111,384 Pre-Funded Warrants, and also received 15,366,490 Common Warrants and OrbiMed Genesis Master Fund, L.P. ("Genesis"), a limited partnership organized under the laws of the Cayman Islands, purchased 1,051,021 Shares and 2,022,277 Pre-Funded Warrants, and also received 3,073,298 Common Warrants. The source of funds for such purchases was the working capital of OPI IX and Genesis. As a result of the Blocker, as of the date hereof, the Warrants beneficially owned by the Reporting Persons are not presently exercisable.

In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed GP is the general partner of OPI IX, pursuant to the terms of the limited partnership agreement of OPI IX. Pursuant to this agreement and relationship, OrbiMed GP has discretionary investment management authority with respect to the assets of OPI IX. Such authority includes the power to vote and otherwise dispose of securities held by OPI IX. The number of outstanding Shares of the Issuer attributable to OPI IX is 5,255,106 Shares, which amount excludes Pre-Funded Warrants to purchase 10,111,384 Shares and Common Warrants to purchase 15,366,490 Shares. OrbiMed GP, pursuant to its authority under the limited partnership agreement of OPI IX, may be considered to hold indirectly 5,255,106 Shares, which amount excludes the Warrants. In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed Genesis is the general partner of Genesis, pursuant to the terms of the limited partnership agreement of Genesis. Pursuant to this agreement and relationship, OrbiMed Genesis has discretionary investment management authority with respect to the assets of Genesis. Such authority includes the power to vote and otherwise dispose of securities held by Genesis. The number of outstanding Shares of the Issuer attributable to Genesis is 1,051,021 Shares, which amount excludes Pre-Funded Warrants to purchase 2,022,277 Shares and Common Warrants to purchase 3,073,298 Shares. OrbiMed Genesis, pursuant to its authority under the limited partnership agreement of Genesis, may be considered to hold indirectly 1,051,021 Shares, which amount excludes the Warrants. In addition to the relationships between the Reporting Persons described in Items 2 and 5 above, OrbiMed Advisors is the managing member of OrbiMed GP and OrbiMed Genesis, pursuant to the terms of the limited liability company agreements of OrbiMed GP and OrbiMed Genesis. Pursuant to these agreements and relationships, OrbiMed Advisors and OrbiMed GP have discretionary investment management authority with respect to the assets of OPI IX. OrbiMed Advisors and OrbiMed Genesis have discretionary investment management authority with respect to the assets of Genesis. Such authority includes the power of OrbiMed GP to vote and otherwise dispose of securities held by OPI IX and the power of OrbiMed Genesis to vote and otherwise dispose of the securities held by Genesis. The number of outstanding Shares attributable to OPI IX is 5,255,106 Shares and the number of Shares attributed to Genesis is 1,051,021 Shares, which in each case, excludes the Warrants held by OPI IX and Genesis. Mona Ashiya ("Ashiya"), a member of OrbiMed Advisors, is a member of the Board of Directors of the Issuer and, accordingly, OrbiMed Advisors and OrbiMed GP may have the ability to affect and influence control of the Issuer. From time to time, Ashiya may receive stock options or other awards of equity-based compensation pursuant to the Issuer's compensation arrangements for non-employee directors. Pursuant to an agreement with OrbiMed Advisors and OrbiMed GP, Ashiya is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors and OrbiMed GP, which will in turn ensure that such securities or economic benefits are provided to OPI IX. Registration Rights Agreement In connection with the PIPE, the Issuer entered into a registration rights agreement (the "Registration Rights Agreement") with the PIPE Investors, including OPI IX and Genesis, pursuant to which the Issuer agreed that, within 30 calendar days after the closing of the PIPE, the Issuer will file with the SEC (at the Issuer's sole cost and expense) a registration statement registering the resale of the Shares purchased in the PIPE. The foregoing descriptions of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Registration Rights Agreement, which is filed as Exhibit 2 and incorporated herein by reference.

------------ ------------------------------------------------------------------- Exhibit Description ------------ ------------------------------------------------------------------- 1. Joint Filing Agreement among OrbiMed Advisors LLC, OrbiMed Genesis GP LLC, and OrbiMed Capital GP IX LLC. -------------------------------------------------------------------------------- 2. Registration Rights Agreement (incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K (File No. 001-39593) filed with the SEC on August 5, 2025. --------------------------------------------------------------------------------